Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2020-07-01
Ráidu:	Endocrinology, Diabetes & Metabolism
Fáttát:	albuminuria CCR2 diabetes kidney MCP‐1 propagermanium
Liŋkkat:	https://doi.org/10.1002/edm2.159
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!